A Novel <sup>111</sup>In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer
Kristell L.S. Chatalic(Erasmus MC), Wytske M. van Weerden(Erasmus MC), Sander Hoeben(Erasmus MC), Marion de Jong(Shell (Netherlands)), Gerben A. Koning(Università Cattolica del Sacro Cuore), Joke Veldhoven-Zweistra(Erasmus MC), Michiel Bolkestein, Otto C. Boerman(Breast Cancer Research Foundation)
Cited by 135
Related Papers
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
|European Journal of Nuclear Medicine and Molecular Imaging|2001|471
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
|Endocrine Related Cancer|2009|462
Overcoming Limitations in Nanoparticle Drug Delivery: Triggered, Intravascular Release to Improve Drug Penetration into Tumors
|Cancer Research|2012|458
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
|Seminars in Nuclear Medicine|2002|433
Plasma Membrane Transport of Thyroid Hormones and Its Role in Thyroid Hormone Metabolism and Bioavailability
|Endocrine Reviews|2001|389